The Big Beautiful Bill Fixes One Drug Problem—But Highlights An Even Bigger One

FORBES

Buried within the One Big Beautiful Bill Act, which President Donald Trump signed into law July 4, is a provision that could improve or even save the lives of the 30 million Americans suffering from rare diseases.

That provision is the Orphan Cures Act, which exempts certain drugs that treat rare diseases from the scheme of price controls Democrats established in Medicare as part of the 2022 Inflation Reduction Act. The first round of price controls takes effect on ten medicines dispensed through the Part D drug benefit in January 2026.

Read more here.

Previous
Previous

Delinking PBM Compensation From Drug List Prices Could Unleash Major Savings

Next
Next

The Culprit Impeding Drug Competition Is Not Who The Feds Expected